BI-505

BIOLOGICAL3 trials

Sponsors

BioInvent International AB

Conditions

Multiple MyelomaSmoldering Multiple Myeloma

Phase 1

A Study of a Human Anti-Intercellular Adhesion Molecule-1 Monoclonal Antibody, in Patients With Multiple Myeloma

CompletedNCT01025206

BioInvent International ABMultiple Myeloma

Start: 2009-12-31End: 2013-02-28Updated: 2013-03-15

A Phase I/II Study of BI-505 in Conjunction With Autologous Stem Cell Transplant in Multiple Myeloma

TerminatedNCT02756728

BioInvent International ABMultiple Myeloma

Start: 2016-05-31End: 2016-12-31Updated: 2020-03-12

Phase 2

A Phase II Study of BI-505 in Smoldering Multiple Myeloma

TerminatedNCT01838369

BioInvent International ABSmoldering Multiple Myeloma

Start: 2013-03-31End: 2014-12-31Updated: 2023-01-11

Related Papers

A single-arm, open-label, phase 2 clinical trial evaluating disease response following treatment with BI-505, a human anti-intercellular adhesion molecule-1 monoclonal antibody, in patients with smoldering multiple myeloma

PLoS ONE2017-02-0351 citations

A Phase I Dose-Escalation Study of Antibody BI-505 in Relapsed/Refractory Multiple Myeloma

Clinical Cancer Research2015-02-2649 citations